Oxford Biomedica and Orchard Initiate New Project Utilizing Oxford’s Lentiviral Technology
August 2, 2022
Oxford Biomedica said that it has initiated a new project with Orchard Therapeutics utilizing the company’s proprietary LentiStable technology.
As part of the project, Oxford Biomedica’s LentiStable technology platform will be used to develop a producer cell line capable of stably expressing lentiviral vectors. Using this technology, the project will be focused on developing high-performing candidate clones for Orchard Therapeutics’ OTL-203, an investigational hemopoietic stem cell (HSC) gene therapy in development for the potential treatment of mucopolysaccharidosis type I Hurler’s syndrome (MPS-IH). As part of an existing collaboration, established in November 2016, Orchard Therapeutics will explore the technology to increase the manufacturing efficiency and scalability of HSC gene therapy.
“This project underscores Orchard’s commitment to continued innovation in all aspects of our operations, including manufacturing. The evaluation of stable cell producer lines is part of our focus on establishing a sustainable lentiviral vector manufacturing platform,” said Nicoletta Loggia, chief technical officer of Orchard Therapeutics.
Oxford Biomedica’s LentiStable technology platform, which is the result of more than 10 years of optimization work, allows the development of a mammalian cell line which can use a chemical inducer to generate viral vector production without the need for transient transfection. The company says this technology has the potential to deliver highly efficient producer cell lines to enable streamlined, scalable, and cost-effective manufacturing.
“We are committed to innovation and to the ongoing development of our platform, which is key to our goal of widening access to gene therapy by lowering the cost of viral vector manufacturing,” said Kyriacos Mitrophanous, chief scientific officer of Oxford Biomedica.
Author: Rare Daily Staff
Sign up for updates straight to your inbox.